Bill Creates National Blood Cancer Program

Summary#

The CARE for Blood Cancer Act of 2026 would create a new National Blood Cancer Program, run by the Secretary of Health and Human Services (HHS). Its stated goal is to improve blood cancer information, health-professional education, support for patients and caregivers, and monitoring of program activities; those goals are not guaranteed results.

  • HHS would have to coordinate, support, and align program activities across federal agencies, including the CDC, NIH, and HRSA.
  • HHS would have to award grants for research and public and professional awareness and education. Eligible applicants include certain government health agencies, organizations, and qualified nongovernmental entities.
  • HHS would have to award grants to eligible higher-education institutions, consortia, and academic medical centers for research to improve access to blood cancer tests and treatments.
  • Grant priorities under the awareness and education program would include applications focused on high-risk communities or areas with substantial blood cancer rates.
  • HHS would have to provide educational materials and programming for health professionals and report to Congress annually on grants, estimated service eligibility, people served, and access barriers.

What it means for you#

  • People with blood cancer and caregivers: The bill names support for patients and caregivers, including through treatments and clinical trials, as a program goal. But it does not set up a direct service, guarantee treatment or trial access, or explain how anyone would receive support.
  • Researchers and eligible institutions: Certain institutions could apply for grants for research on awareness, education, screening, treatments, risk factors, and genetic predispositions. The bill does not set application rules or guarantee any applicant a grant.
  • Health professionals: HHS would have to establish educational materials and programming to improve professionals’ skills in detecting and controlling blood cancer.
  • State, local, territorial, and Tribal health agencies and organizations, and qualified nongovernmental entities: These groups could be eligible for awareness and education grants. The bill requires priority for applications focused on certain high-risk communities or areas, but does not define “high risk” or “substantial” rates.
  • The public: The bill does not change insurance coverage, create a right to screening or treatment, or require people to take part in research.

Money#

No publicly available information on estimated costs.

  • The bill requires HHS to award grants and provide educational materials and programming, but gives no funding amounts or staffing estimates.
  • It does not specify a funding source or appropriate a stated amount.
  • Grant amounts and the cost of running the program are unknown.

What is unclear#

  • The bill does not define “blood cancer,” “high risk,” or “substantial” rates.
  • It does not set grant application, selection, payment, or oversight rules, or say how much money would be available.
  • It does not explain what services people could receive or how they would qualify, even though the annual report must estimate who is eligible for services and count people served.
  • It does not say how HHS would involve patients, caregivers, or Tribal communities in running the program.
  • The bill has no start date. It is a bill introduced in the House, not a law; whether it will pass is uncertain.

Case for#

  • A possible argument for the bill is that coordinating work across federal health agencies could connect research, public information, and professional education.
  • Grants could support research into earlier detection, treatment approaches, and barriers that affect groups with higher blood cancer rates.
  • Required annual reports could give Congress information about grants, who is served, and barriers to access.

Case against#

  • The bill requires a program and grants but does not provide funding amounts or explain how the program would be staffed. Its duties may therefore be difficult to assess or carry out.
  • It names patient and caregiver support as a goal but does not create a clear service or guarantee access to treatment, trials, or other help.
  • Key terms and grant rules are left open, so the bill does not show how priorities would be measured or how grant decisions would be made.